SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
Quarterly Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
For the Quarter Ended Commission File No. 0-23047
March 31, 2001
SIGA Technologies, Inc.
(Exact name of registrant as specified in its charter)
Delaware 13-3864870
(State or other jurisdiction of (IRS Employer Id. No.)
incorporation or organization)
420 Lexington Avenue, Suite 620
New York, NY 10170
(Address of principal executive offices) (zip code)
Registrant's telephone number, including area code: (212) 672-9100
Securities registered pursuant to Section 12(b) of the Act:
None
(Title of Class)
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.0001 par value
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No |_| .
As of May 11, 2001 the registrant had outstanding 7,550,058 shares of Common
Stock.
================================================================================
SIGA TECHNOLOGIES INC.
(A development stage company)
BALANCE SHEET
March 31, December 31,
2001 2000
------------ ------------
(unaudited)
ASSETS
Current Assets
Cash and cash equivalents .............................................. $ 1,269,106 $ 1,707,385
Accounts receivable .................................................... 15,000 37,800
Prepaid expenses ....................................................... -- 5,644
------------ ------------
Total current assets .................................................. 1,284,106 1,750,829
Equipment, net ......................................................... 941,681 1,027,702
Investments ............................................................ 275,106 275,106
Other assets ........................................................... 158,435 156,556
------------ ------------
Total assets .......................................................... 2,659,328 3,210,193
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable ....................................................... 115,137 209,278
Accrued expenses ....................................................... 317,853 305,912
Capital lease obligations .............................................. 444,754 391,407
Deferred Revenue ...................................................... 575,000 450,000
------------ ------------
Total current liabilities ............................................. 1,452,744 1,356,597
6% Convertible Debt ................................................... 856,372 719,561
Accrued Debenture Interest ............................................ 98,978 80,281
Non current capital lease obligations ................................. (0) 129,018
------------ ------------
Total liabilities .................................................. 2,408,094 2,285,457
============ ============
Commitments and contingencies ............................................. -- --
Stockholders' equity
Preferred stock ($.0001 par value, 10,000,000 shares authorized,
none issued and outstanding) ......................................... -- --
Common stock ($.0001 par value, 25,000,000 shares authorized,
7,471,837 and 6,602,712 issued and outstanding at December 31, 2000
and December 31, 1999, respectively) ................................. 756 747
Additional paid-in capital ............................................. 23,193,085 23,793,983
Deferred Compensation ................................................. (132,847) (428,425)
Deficit accumulated during the development stage ....................... (22,809,760) (22,441,569)
------------ ------------
Total stockholders' equity ............................................ 251,234 924,736
------------ ------------
Total liabilities and stockholders' equity ............................ 2,659,328 3,210,193
============ ============
The accompanying notes are an integral part of these financial statements
SIGA TECHNOLOGIES INC.
(A development stage company)
STATEMENT OF OPERATIONS
For The Period
December 28,
1995 (Date of
Three months ended Inception) to
March 31, March 31,
2001 2000 2001
----------- ----------- --------------
(unaudited) (unaudited)
Revenues
Research and Development Contracts $ 304,500 $ 80,800 $ 2,432,181
----------- ----------- ------------
Operating expenses
General and administrative 65,355 811,232 12,329,511
Research and development 430,610 762,927 10,706,498
Patent preparation fees 17,621 26,337 1,255,112
Settlement of litigation 97,969
Stock option and warrant compensation -- -- 450,450
----------- ----------- ------------
Total operating expenses 513,586 1,600,496 24,839,540
----------- ----------- ------------
Operating loss (209,086) (1,519,696) (22,407,359)
Interest income/(expense) (159,105) (118,236) (313,470)
Loss on impairment of investment (155,591)
Other Income/Gain on sale of securities -- -- 66,660
----------- ----------- ------------
Net loss (368,191) (1,637,932) (22,809,760)
=========== =========== ============
Basic and diluted loss per share (0.05) (0.25)
=========== ===========
Weighted average common shares outstanding used
for basic and diluted loss per share 7,528,628 6,649,290
----------- -----------
The accompanying notes are an integral part of these financial statements
SIGA TECHNOLOGIES INC.
(A development stage company)
STATEMENT OF CASH FLOWS
For The Period
December 28,
1995 (Date of
Three months ended Inception) to
March 31, March 31,
2001 2000 2001
----------- ----------- --------------
(unaudited) (unaudited)
Cash flows from operating activities:
Net loss $ (368,191) $ (947,290) $(22,809,760)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation 86,021 92,459 1,036,907
Stock, options & warrant compensation (387,042) 14,620 1,921,958
Loss on impairment of investment 155,591
Loss on write-off of capital equipment -- -- 97,969
Amortization of debt discount 151,178 -- 873,490
Purchase of rights to certain technology 1,457,458
Realized gain on marketable securities (24,090) (66,660)
Non-cash research and development 500,344
Changes in assets and liabilities:
Accounts receivable 22,800 -- (15,000)
Prepaid expenses and ither current assets 5,644 21,943 --
Other assets (1,879) -- (158,435)
Accounts payable and accrued expenses (82,200) (64,877) 432,990
Deferred Revenue 125,000 -- 575,000
Accrued Interest 20,249 -- 100,530
Deferred Compensation -- --
----------- ----------- ------------
Net cash used in operating activities (428,420) (907,235) (15,897,618)
----------- ----------- ------------
Cash flows from investing activities:
Capital expenditures -- (54,584) (2,157,254)
Sale (purchase) of investment securities -- -- 66,660
Investment in Open-I-Media -- 84,747 (170,000)
----------- ----------- ------------
Net cash flow used in investing activities -- 30,163 (2,260,594)
----------- ----------- ------------
Cash flows from financing activities:
Net proceeds from issuance of common stock -- -- 17,363,056
Receipts of stock subscriptions outstanding -- -- 1,248
Gross proceeds from sale of convertible debentures 1,500,000
Proceeds from exercise of options 65,812 118,586
Net proceeds from sale of warrants 52,174
Convertible debentures and warrants issuance costs (52,500)
Proceeds from bridge notes -- 1,000,000
Repayment of bridge notes -- (1,000,000)
Proceeds from sale & leaseback of equipment -- 1,139,085
Principal payments on capital lease obligations (75,671) (74,992) (694,331)
----------- ----------- ------------
Net cash provided from financing activities (9,859) (74,992) 19,427,318
----------- ----------- ------------
Net increase (decrease) in cash and cash equivalents (438,279) (952,064) 1,269,106
Cash and cash equivalents at beginning of period 1,707,385 4,966,873 --
----------- ----------- ------------
Cash and cash equivalents at end of period $ 1,269,106 $ 4,014,809 $ 1,269,106
=========== =========== ============
During the quarter ended March 31, 2001, certain creditors of the Company
converted notes payable into equity in the amount of $15,918.
The accompanying notes are an integral part of these financial statements
SIGA Technologies, Inc.
NOTES TO THE MARCH 31, 2001 FINANCIAL STATEMENTS
1. Basis of Presentation
The financial statements of Siga Technologies, Inc. (the "Company") have been
prepared in accordance with generally accepted accounting principles for interim
financial information and the rules of the Securities and Exchange Commission
(the "SEC") for quarterly reports on forms 10-QSB and do not include all of the
information and footnote disclosures required by generally accepted accounting
principles for complete financial statements. These statements should be read in
conjunction with the Company's audited financial statements and notes thereto
for the year ended December 31, 2000, included in the 2000 Form 10-KSB.
In the opinion of management, the accompanying unaudited financial statements
include all adjustments, consisting of normal adjustments, necessary for a fair
presentation of the results of operations for the interim periods. The results
of operations for the three months ended March 31, 2001 are not necessarily
indicative of the results of operations to be expected for the full year ending
December 31, 2001.
The accompanying financial statements have been prepared assuming that the
company will continue as a going concern. Management believes that current
resources will be sufficient to support its planned operations through the end
of December 2001. However, in the event that the Company is unable to raise
additional funds, planned operations will need to be scaled back or
discontinued.
2. Stockholders' Equity
In January 2000 the Company completed a private placement of 6% convertible
debentures at an aggregate principal amount of $1,500,000 and 1,043,478 warrants
to purchase shares of the Company's common stock with a purchase price of $0.05
per warrant. The Company received net proceeds of $1,499,674 from the total
$1,552,174 gross proceeds raised. The debentures are convertible into common
stock at $1.4375 per share. Interest at the rate of 6% per annum is payable on
the principal of each convertible debenture in cash or shares of the Company's
common stock, at the discretion of the Company upon conversion or at maturity.
The warrants have a term of five years and are exercisable at $3.4059 per share.
In May 2001, certain debenture holders entered into a Conversion Agreement with
the Company under which they will convert an aggregate of approximately
$1,291,000 of their debentures and accrued interest into shares of the Company's
Series A convertible preferred stock, $0.0001 par value per share.
In August 2000 the Company entered into an agreement with a consultant to
provide the Company with financial consulting, planning, structuring, business
strategy, and public relations services and raising equity capital. The term of
the agreement was for a period of fifteen months with a guarantee of a six-month
retention from August 1, 2000, through February 1, 2001. The consultant was paid
a fee of $40,000 upon signing of the agreement, and was to be paid an additional
$40,000 every two months for the term of the agreement unless terminated by the
Company at the end of the initial six month period.
Under the provisions of the agreement, the consultant received warrants to
purchase 500,000 shares of the Company's common stock. 200,000 warrants with an
exercise price of $3.63 per share vested upon the date of the agreement. Of the
remaining 300,000 warrants, 100,000 warrants were to vest on May 1, 2001 with an
exercise price of $6.50 per share, 100,000 were to vest on August 1, 2001 with
an exercise price of $7.50 per share and 100,000 were to vest on October 1, 2001
with an exercise price of $9.50 per share. During the year ended December 31,
2000, the Company recorded a non-cash charge associated with such warrants in
the amount of $645,786.
In January 2001 the Company and the consultant terminated their arrangement. In
addition to the cancellation of 300,000 unvested warrants, the consultant agreed
to return 150,000 of its vested warrants to the Company. In connection with the
cancellation and return of the vested warrants, the Company recorded a non-cash
benefit of $535,000 in the results of its operations for the three months ended
March 31, 2001.
3. Employment Agreements
In January 2000, the Company entered into employment agreements with its
Chief Executive Officer and its Chairman (the "EVPs"), expiring in January 2005.
The new agreements provided for an annual salary of $250,000, with annual
increases of at least 5%. In addition, both of the EVPs were granted
fully-vested options to purchase 500,000 shares of the Corporations' common
stock at $2.00 per share. Under the provisions of the agreements the EVPs would
each receive a cash payment equal to 1.5% of the total consideration received by
the Company in a transaction resulting in a greater than 50% change in ownership
of the outstanding common stock of the Company.
In January 2000, the Company and its Chief Financial Officer ("CFO") entered
into an amendment to the CFO's employment agreement, extending his employment
until April 2002. Under this amendment, the CFO received options to purchase
100,000 shares of the Company's common stock at $2.00 per share. The options
vest ratably over two years and expire in January 2010.
In October 2000, the Company entered into amended and restated employment
agreements with its Chief Executive Officer and its Chairman. Under the amended
agreements, in the event of a change in control, the EVPs will be paid their
respective compensation for the remainder of their employment terms and will
receive a tax gross-up payment. In addition, in such event, all unvested options
held by the EVPs will become vested and exercisable. In the event of a merger or
consolidation where the holders of the voting capital stock of the Company
immediately prior to the transaction own less than a majority of the voting
capital stock of the surviving entity, the EVPs will each receive a one time
cash payment of 1.5% of the total consideration received by the Company. In the
event of a sale, merger or public spin-out of any subsidiary or material asset
of the Company, the EVPs shall each receive a fee equal to 1.5% of the value of
the Company's shares of the subsidiary or material asset
On March 30, 2001, the Company, its EVPs and certain investors (the "Investors")
in the Company entered into an agreement under which the EVP's agreed to resign
from Siga and use their best efforts to cause each of the current directors of
Siga to resign. Under the agreement, certain Investors were to be appointed as
Chairman of the Board and as Chief Executive Officer. In addition, as prescribed
in the agreement, the amended employment agreement entered into by the Company
and the EVPs in October 2000 was terminated with no cost to the Company, the
vesting of 37,500 options granted to the EVPs was accelerated, exercise terms
were extended and the EVPs are entitled to certain benefits until April 2003. In
addition, each of the parties to the agreement have agreed to lock up their
respective shares of common stock and options of Siga for 24 months subject to
certain release provisions. In connection with the amendment of the terms of the
EVP's options, the Company recorded a non-cash charge of $73,000 in the three
months ended March 31, 2001.
4. Subsequent Events
In May 2001, the Company signed an amendment to the agreement with Wyeth-Ayerst
extending their funding of the Company's research through September 2001. As a
result, the previously recorded deferred revenue of $562,500 as of March 31,
2001, will be recorded as revenue in the second quarter 2001.
In May 2001, the Company raised gross proceeds of $725,000 in a private offering
of common stock and warrants to purchase shares of the Company's common stock.
The Company sold 362,500 shares of common stock and 362,500 warrants. The
warrants have a term of seven years and are exercisable at $2.94.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF
OPERATIONS
The following discussion should be read in conjunction with our financial
statements and notes to those statements and other financial information
appearing elsewhere in this Quarterly Report. In addition to historical
information, the following discussion and other parts of this Quarterly Report
contain forward-looking information that involves risks and uncertainties.
Overview
We are a development stage, technology company, whose primary focus is in
biopharmaceutical product development. Since inception in December 1995 our
efforts have been principally devoted to research and development, securing
patent protection, obtaining corporate relationships and raising capital. Since
inception through March 31, 2001, we have sustained cumulative net losses of
$22,809,760, including non-cash charges in the amount of $1,457,458 for the
write-off of research and development expenses associated with the acquisition
of certain technology rights acquired from a third party in exchange for our
common stock. Our losses have resulted primarily from expenditures incurred in
connection with research and development, patent preparation and prosecution and
general and administrative expenses. From inception through March 31, 2001,
research and development expenses amounted to $10,706,498, patent preparation
and prosecution expenses totaled $1,255,112, general and administration expenses
amounted to $12,329,511. From inception through March 31, 2001 revenues from
research and development agreements and government grants totaled $2,432,181.
As of March 31, 2001, Siga has limited resources, has incurred
cumulative net operating losses of $22,809,760 and expects to incur additional
losses to perform further research and development activities. We do not have
biomedical products which are commercially available, and we do not expect to
have such for several years, if at all. We believe that we will need additional
funds to complete the development of our biomedical products. These
circumstances raise substantial doubt about our ability to continue as a going
concern. Our plans with regard to these matters include continued development of
our products as well as seeking additional research support funds and financial
arrangements. Although we continue to pursue these plans, there is no assurance
that we will be successful in obtaining sufficient financing on terms acceptable
to us. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.
We have consolidated our biotechnology assets and operations in our
research facility in Corvallis, Oregon. We continue to seek to fund a major
portion of our ongoing vaccine and antibiotic programs through a combination of
government grants, corporate partnerships and strategic alliances. While we have
had success in obtaining partners and grants, no assurance can be given that we
will continue to be successful in obtaining funds from these sources. Until
additional relationships are established, we expect to continue to incur
significant research and development costs and costs associated with the
manufacturing of product for use in clinical trials and pre-clinical testing. It
is expected that general and administrative costs, including patent and
regulatory costs, necessary to support clinical trials and research and
development will continue to be significant in the future. If we are unable to
raise needed capital, our operations will need to be scaled back or
discontinued.
To date, we have not marketed, or generated revenues from the commercial
sale of any products. Our biopharmaceutical product candidates are not expected
to be commercially available for several years, if at all. Accordingly, we
expect to incur operating losses for the foreseeable future. There can be no
assurance that we will ever achieve profitable operations.
Results of Operations
Three Months ended March 31, 2001 and March 31, 2000
Revenues from grants and research and development contracts were $304,500
for the three months ended March 31, 2001 compared to $80,800 for the same
period of 2000. The approximate 277% increase in revenue for the period ended
March 31, 2001 is the result of receiving a $237,500 payment from Wyeth Ayerst
for achieving a research and development milestone under our July 1997 agreement
with Wyeth-Ayerst. During the three month period of 2001 we received an
additional $112,500 from Wyeth-Ayerst in continued support for our research
efforts, however, pending completion of an extension amendment to the July 1997
agreement, the entire amount has been recorded as deferred revenue.
General and administrative expenses decreased approximately 92% for the
three months ended March 31, 2001 to $65,355 from $811,232 for the three months
ended March 31, 2000. The decrease in expenses is primarily the result of a
credit for non-cash compensation totaling $534,885. The credit resulted from the
cancellation of certain vested warrants granted to a consultant in connection
with a termination agreement in a prior period. Also contributing to the decline
in expenses is the elimination of certain general and administration management
positions associated with our internet assets. Further, for the three months
ended March 31, 2000 we incurred non-cash charges of $144,452 for warrants
granted to certain directors under consulting agreements. No such charges were
incurred during the three months ended March 31, 2001.
Research and development expenses declined to $430,610 for the three
months ended March 31, 2001 from $762,927 for the same period in 2000. The
approximate 44% decrease in spending in the current year period is primarily the
result of our sale of internet assets in the third quarter of 2000. For the
three months ended March 31, 2000 we incurred approximately $423,000 of expenses
for the development of our internet assets. In the three month period ended
March 31, 2001 no such charges were incurred. Research and development spending
for our biotechnology projects increased in the three months ended March 31,
2001 by approximately 27% over the prior year period. This increase reflects our
heightened focus on our core biotechnology operations.
Patent preparation expense of $17,621 for the three months ended March 31,
2001 was approximately 33% lower than the $26,337 incurred for the three months
ending March 31, 2000. The decline in spending from the prior year three month
period reflects the continuing trend to reduce patent costs by focusing on our
core biopharmaceutical technologies and eliminating programs that we believe
have less commercial value.
Net interest expense for the three months ended March 31, 2001 was
$159,105 compared to expenses of $118,236 for the three months ended March 31,
2000. The increase in net interest expense is the result of the accrual of
interest expense associated with our sale of $1,500,000 principal amount of 6%
convertible debentures in January 2000. In the prior year three month period,
the debentures were outstanding for two months of such period compared to three
months in the current year three month period.
Net loss for the three months ended March 31, 2001 was $368,191, an
approximate 78% decrease from the $1,637,932 loss incurred for the three months
ended March 31, 2000. The decrease in the operating loss was primarily due to
the elimination of research and development expenses associated with development
of our internet assets as well as the significant reduction of general and
administrative expenses resulting from the return of warrants by a consultant
and a reduction in payroll expense as detailed above.
Liquidity and Capital Resources
As of March 31, 2001 we had $1,269,106 in cash and cash equivalents. In
July of 1997 we entered into a collaborative two year research and license
agreement with Wyeth-Ayerst. Under the terms of the agreement, we have granted
Wyeth-Ayerst an exclusive worldwide license to develop, make, use and sell
products derived from specified technologies. The agreement required
Wyeth-Ayerst to sponsor further research by us for the development of the
licensed technologies for a period of two years from the effective date of the
agreement. An amendment to the agreement extended its term through September
1999. Through March 31, 2001 we have recorded a total of $2,037,500 of revenue
from Wyeth-Ayerst. We have received an additional $562,500 in payments from
Wyeth-Ayerst through March 31, 2001 and an additional $112,500 in May 2001,
however, pending completion of an extension amendment to the agreement with
Wyeth-Ayerst, the payments have been recorded as deferred revenue.
In May 2001 holders of the Company's 6% convertible debentures, consisting
of an aggregate principal amount $1,200,000 and approximately $91,000 of accrued
interest agreed to convert the debt and interest into convertible preferred
stock. The converting debenture holders will receive preferred shares at a
conversion price of $1.4375 per share. The preferred shares will have a
cumulative dividend of 6% per annum payable in cash or preferred stock at Siga's
discretion. The shares are convertible into common stock on a one for one basis.
Each holder of preferred stock is entitled to the number of votes into which the
shares of preferred stock are convertible into common.
On May 8, 2001 we completed a private placement of an aggregate of 362,500
shares of common stock and 362,500 warrants. We received gross proceeds of
$725,000. The warrants have a term of seven years and are exercisable at $2.94
per share.
On May 11, 2001, we entered into an amendment to the July 1997
Collaborative Research and License Agreement between Siga and the Wyeth-Ayerst
Laboratories Division of American Home Products Corporation. The amendment
extends the term of the Agreement to September 1, 2001. The extension provides
for Wyeth Ayerst to continue to pay Siga at a rate of $450,000 per year through
the term of the amended agreement. Since the completion of the term of the
agreement as amended, September 30,1999 through March 31, 2001, we have received
$562,500 from Wyeth Ayerst to support work performed by Siga under the
agreement. These payments have been recorded as deferred revenue, and will be
recorded as revenue in the second quarter 2001.
We anticipate that our current resources will be sufficient to finance our
currently anticipated needs for operating and capital expenditures approximately
through year end of 2001. In addition, we will attempt to generate additional
working capital through a combination of collaborative agreements, strategic
alliances, research grants, equity and debt financing. However, no assurance can
be provided that additional capital will be obtained through these sources or,
if obtained, on commercially reasonable terms. If we are unable to raise
additional capital when needed, we may be forced to curtail certain activities
and programs or possibly cease operations altogether.
Our working capital and capital requirements will depend upon numerous
factors, including pharmaceutical research and development programs;
pre-clinical and clinical testing; timing and cost of obtaining regulatory
approvals; levels of resources that we devote to the development of
manufacturing and marketing capabilities; technological advances; status of
competitors; and our ability to establish collaborative arrangements with other
organizations.
Part II
Other information
Item 1. Legal Proceedings - None
Item 2. Changes in Securities and Use of Proceeds
In May 2001 holders of the Company's 6% convertible debentures,
consisting of an aggregate principal amount $1,200,000 and approximately $91,000
of accrued interest agreed to convert the debt and accrued interest into
convertible preferred stock. The converting debenture holders will receive
preferred shares at a conversion price of $1.4375 per share. The preferred
shares will have a cumulative dividend of 6% per annum payable in cash or
preferred stock at Siga's discretion. The shares are convertible into common
stock on a one for one basis. Each holder of preferred stock is entitled to the
number of votes into which the shares of preferred stock are convertible into
common. Exemption from registration for this transaction was claimed pursuant to
Section 4 (2) of the Securities Act of 1933, as amended, by an issuer not
involving a public offering.
On May 8, 2001 we completed a private placement of an aggregate of 362,500
shares of common stock and 362,500 warrants. We received gross proceeds of
$725,000. The warrants have a term of seven years and are exercisable at $2.94
per share. Exemption from registration for this transaction was claimed pursuant
to Section 4 (2) of the Securities Act of 1933, as amended, by an issuer not
involving a public offering. This transaction was completed without general
solicitation or advertising and was offered only to accredited investors.
Item 3. Defaults upon Senior Securities - None
Item 4. Submission of Matters to a Vote of Security Holders - None
Item 5. Other Information
On March 30, 2001, Joshua D. Schein, our Chief Executive Officer and a
director and Judson A. Cooper, our Chairman of the Board entered into an
agreement with among others, Donald G. Drapkin, a beneficial owner of more than
5% of our common stock, in which Messrs. Schein and Cooper agreed to resign from
Siga and use their best efforts to cause each of the current directors of Siga
to resign. On April 19, 2001 Mr. Drapkin was appointed Chairman of the Board and
Eric A. Rose, M.D. was appointed Interim Chief Executive Officer. In addition,
Gabriel M. Cerrone, Thomas E. Constance, Mehmet C. Oz, M.D. and Michael Weiner,
M.D. were appointed as directors. Each of the parties have agreed to lock up
their shares of common stock and options of Siga for 24 months subject to
certain conditions and exceptions. A Schedule 14f-1 was sent to our shareholders
of record on April 9, 2001. On April 19, 2001 our current directors resigned and
on April 20, 2001 the resignations of Messrs. Schein and Cooper became
effective.
Item 6. Exhibits and Reports on Form 8-K - None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has fully caused the report to be signed on its behalf by the
undersigned, thereunto duly authorized.
SIGA Technologies, Inc.
(Registrant)
Date: May 15, 2001 By: /s/ Thomas N. Konatich
----------------------------
Thomas N. Konatich
Chief Financial Officer
(Principal Accounting Officer and
Financial Officer and Vice
President, Finance)